Lamotrigine

Limits on what this shows

• Key negative/null findings: A narrative review of antiepileptic drugs and mitochondrial function (Finsterer and Scorza, 2017, PMID 28732239) surveys the class without lamotrigine-level stratification of outcomes in every comparison it makes; it is treated here as Tier C class-level context, not primary support.
• At-risk subgroups: None identified; this is a protective-direction finding, not a risk.
• Counter-evidence on record: No animal or human study located in this review reports lamotrigine impairing mitochondrial structure or function; the direction is consistently protective across the sources found.

Regulatory status

Not addressed in the FDA label; no labeled mitochondrial toxicity or benefit claim.

Population evidence

Fu XX et al. (2025, PMID 39834280) report that modulation of mitochondrial function contributes to lamotrigine's protective effect in an Alzheimer's disease model. Bortolasci CC et al. (2021, PMID 32295468) tested lamotrigine directly in cultured neuronal-like and microglial cell lines and report effects on cellular bioenergetic pathways. Both used lamotrigine specifically, not a class surrogate; both are preclinical (animal/cell-culture), not human cohort, work.

Mechanism

Proposed stabilization of mitochondrial membrane function and bioenergetic signaling, consistent with lamotrigine's broader neuroprotective pharmacology (sodium-channel stabilization reducing excitotoxic calcium and metabolic load on neurons).

Counter-evidence held on record

This is preclinical, animal and cell-culture evidence only. It must never be presented to a consumer as a demonstrated human mitochondrial benefit, and it does not support a supplement or dosing recommendation of any kind.

Limits on what this shows

• Key negative/null findings: This review located no drug-specific animal or human study reporting lamotrigine increasing oxidative stress markers; the seven sources found are unanimous in direction. No human biomarker study (Tier A) was located either way.
• At-risk subgroups: Not applicable; protective-direction, preclinical finding.
• Counter-evidence on record: None found contradicting the direction; the caveat is entirely about species and translation to humans, not about direction.

Regulatory status

Not addressed in the FDA label.

Population evidence

Eren I, Naziroglu M, Demirdas A (2007, PMID 17401662), "Protective effects of lamotrigine...on depression-induced oxidative stress"; Arora T et al. (2010, PMID 20002063), lamotrigine and oxidative stress during chemical epileptogenesis; Agarwal NB et al. (2011, PMID 21247777), lamotrigine and oxidative stress in PTZ-kindled mice; Abelaira HM et al. (2013, PMID 23416280), lamotrigine and oxidative parameters in a chronic mild stress model; Ozkul A et al. (2014, PMID 24664417), lamotrigine and oxidative-nitrosative stress with spatial learning; Sarangi SC et al. (2016, PMID 27834333), lamotrigine and oxidative stress alongside levetiracetam and topiramate; Kaplan EN, Eren I, Naziroglu M (2025, PMID 40968619), lamotrigine decreasing oxidative stress and apoptosis in a bipolar-disease model. All seven used lamotrigine directly in the tested arm, in rodent models, not as a class surrogate.

Mechanism

Proposed antioxidant/neuroprotective action reducing lipid peroxidation and reactive oxygen/nitrogen species in brain tissue, converging across independent laboratories and disease models (seizure, depression, mania) rather than resting on one group's finding.

Counter-evidence held on record

Rodent-model findings do not establish a human antioxidant benefit and must not be marketed as one. This entry exists to correct, not reinforce, any "anticonvulsants cause oxidative damage" framing circulating for the drug class; see also the fails-verification section for the adjacent folate and vitamin D claims this class framing tends to travel with.

Limits on what this shows

• Key negative/null findings: The same study reports no significant trace-element difference among the other monotherapy subgroups outside the two named exceptions, and the summary retrieved for this review does not report a lamotrigine-versus-healthy-control comparison for iron specifically, a gap that full-text access would be needed to close.
• At-risk subgroups: Unknown; the source subgroup (n=4) is too small to characterize a clinical risk group.
• Counter-evidence on record: No other drug-specific human or animal study of lamotrigine and iron status was located despite completed searches this session across PubMed search-listing pages (phrasings including "lamotrigine iron," "lamotrigine trace element," and "lamotrigine ferritin"), the Crossref API, and OpenAlex.

Regulatory status

Not addressed in the FDA label; iron status is not among the labeled hematologic warnings, which concern immune-mediated dyscrasias rather than trace-element status.

Population evidence

Sarangi SC, Tripathi M, Kakkar AK, Gupta YK (2014, PMID 24679946, Epilepsy Research), a cross-sectional study of 307 people with epilepsy and 42 healthy controls at a tertiary care hospital in northern India, measured ten trace elements by inductively coupled plasma-atomic emission spectrometry across five monotherapy subgroups: valproate (n=50), carbamazepine (n=47), phenytoin (n=49), levetiracetam (n=21), and lamotrigine (n=4). The abstract states that AED monotherapy groups showed minimal differences from each other, "except higher nickel level in levetiracetam group and low iron level in lamotrigine group compared to VPA group." Lamotrigine was directly in the studied cohort, not a class surrogate, but the subgroup is four patients.

Mechanism

None proposed in the source or established elsewhere in lamotrigine pharmacology; lamotrigine has no documented absorption-interference, chelation, or renal-wasting mechanism for iron (see pharmacokinetic basis above). The comparison is to the study's valproate subgroup, not to its own healthy controls, so it is equally possible that valproate elevates iron rather than lamotrigine lowering it; the available text does not resolve this, an active-comparator limitation that should be stated plainly rather than read as depletion.

Counter-evidence held on record

This is a single four-patient, active-comparator finding, not a confirmed deficit against normal iron status, and it must never be presented as a reason to supplement iron. It is also unrelated to the labeled hematologic dyscrasia risk graded separately above; a low blood count on lamotrigine warrants clinical evaluation under that entry, not iron repletion based on this one.

Limits on what this shows

• Why no grade: Dual condition met: the one Tier A source with lamotrigine in the cohort (Sarangi SC et al. 2014, PMID 24679946) reports copper levels "similar" to healthy controls across the monotherapy subgroups other than levetiracetam, including the four-patient lamotrigine group, a null rather than a positive finding, so it does not support even a yellow grade; and no circulating depletion or excess claim was found on the consumer sources checked (RxList Lamictal page, reviewed directly, has no nutrient-depletion content of any kind).

Channels tried, this revision

PubMed search-listing pages completed cleanly for "lamotrigine copper" (9 results, none copper-status-relevant beyond the trace-element study noted below; one result, Najm et al. 2021, PMID 33778282, is synthetic chemistry describing novel lamotrigine-copper Schiff base complexes as anticancer/anticonvulsant drug candidates, not a study of physiological copper status, and is excluded on that basis) and for "lamotrigine ceruloplasmin" (zero results, a clean null). The Crossref Works API completed cleanly for "lamotrigine copper" (no copper-status-relevant match). OpenAlex per-PMID lookups confirmed source metadata for the candidates found. Europe PMC and Semantic Scholar remained rate-limited (HTTP 429) throughout this session despite repeated retries across hosts and phrasings and could not be reached for this category.

Assessment

This is now a confirmed, actively researched gap rather than a tooling-blocked one: the only lamotrigine-specific data point found is a null result in a small subgroup, and no claim circulates to rebut. Re-running the same PubMed/Crossref queries adds little; the highest-value next step for a later revision is full-text access to Sarangi et al. 2014 to confirm the copper comparison basis against healthy controls specifically, and any larger or replication cohort that may since have been published.

Limits on what this shows

• Key negative/null findings: A separate 2026 narrative review (Zammar K et al., PMID 42541365, Epilepsia Open) names lamotrigine among anti-seizure medications subject to microbial biotransformation but is a class-level synthesis without drug-specific primary data of its own, so it is treated as Tier C supporting context, not primary evidence for this grade. No study located in this review reports lamotrigine having no effect on gut bacterial growth.
• At-risk subgroups: None established in humans; the tested concentration (2000 uM) is an in vitro exposure level not confirmed to reflect achievable gut-luminal concentrations in patients, a limitation this review could not verify further from the material retrieved.
• Counter-evidence on record: None found contradicting the direction; the caveat is entirely that this is in vitro, not human, evidence, and that the tested concentration's clinical relevance is unconfirmed.

Regulatory status

Not addressed in the FDA label.

Population evidence

Ilhan ZE, Brochard V, Lapaque N, Auvin S, Lepage P (2022, PMID 35183703, Neurobiology of Disease) tested nine anti-seizure medication active ingredients, including lamotrigine directly and not as a class surrogate, against cultured early-life gut bacterial strains and colon epithelial cell lines. At 2000 uM, lamotrigine inhibited at least 25% of the growth of 19 bacterial strains, reduced the growth of more than ten strains overall, showed greater toxicity on Gram-positive than Gram-negative strains, and inhibited Actinobacteria, including Bifidobacterium species, more than Bacteroidetes (Student's t-test P=0.026). Lamotrigine also significantly reduced colon epithelial cell proliferation versus vehicle control, more potently than carbamazepine, and induced the apoptosis marker cas3 more than two-fold, alongside carbamazepine and phenytoin. Bifidobacterium longum supernatant partially protected epithelial cell proliferation against lamotrigine (Tukey's adjusted P=0.02).

Mechanism

Direct antimicrobial and cytotoxic action of lamotrigine on cultured gut bacterial strains and colon epithelial cells, with phylum-level selectivity (greater effect on Gram-positive organisms and Actinobacteria) and partial rescue by a probiotic-species supernatant, suggesting microbial metabolites can modulate the effect. No human gut-microbiome composition study was located.

Counter-evidence held on record

This is in vitro, cultured-bacteria evidence only, at a fixed high concentration of uncertain clinical relevance. It must never be presented as a demonstrated human microbiome-disruption effect, and it does not support a probiotic, dosing, or supplement recommendation of any kind.

Limits on what this shows

• Key negative/null findings: The label does not describe these dyscrasias as dose-dependent in the way a nutritional deficiency anemia would be, and does not link them to measured iron, B12, or folate status.
• At-risk subgroups: Patients with a history of the lamotrigine hypersensitivity syndrome, rapid dose titration outside the labeled schedule, and pediatric patients, who carry a higher labeled rash/hypersensitivity risk generally.
• Counter-evidence on record: RxList's consumer-facing Lamictal page, checked for this dossier, does not frame any hematologic effect as nutrient-related, consistent with the outcome-not-deficiency reading used here.

Regulatory status

Labeled adverse reaction in Warnings and Precautions of the current U.S. prescribing information, alongside hemophagocytic lymphohistiocytosis (HLH), a related severe immune-activation syndrome.

Population evidence

Post-marketing and clinical-trial pharmacovigilance data compiled by the manufacturer and FDA; frequency is characterized in the label as uncommon to rare rather than quantified as a single incidence figure across the whole treated population.

Mechanism

Idiosyncratic, immune-mediated bone-marrow and blood-cell effects, frequently but not exclusively linked to the multiorgan hypersensitivity reaction associated with lamotrigine-associated rash. This is a labeled drug toxicity, not a nutrient-cofactor deficiency; iron, copper, and B12 status were not implicated in the label's own causal account.

Counter-evidence held on record

This is a hematologic adverse-reaction risk, not an iron, copper, or B12 deficiency. Per governing rule, an anemia the drug's own label attributes to bone-marrow or immune-mediated dyscrasia must never be recommended for treatment with iron, B12, or copper supplementation; any cytopenia on lamotrigine warrants a CBC and clinical evaluation, not empiric nutrient repletion.

Limits on what this shows

• Key negative/null findings: No human ATP-production or cellular energy-metabolism study in lamotrigine-treated patients was located in this review.
• At-risk subgroups: None identified.
• Counter-evidence on record: None found.

Regulatory status

Not addressed in the FDA label.

Population evidence

Bortolasci CC et al. (2021, PMID 32295468), "Effects of psychoactive drugs on cellular bioenergetic pathways," tested lamotrigine directly in cultured neuronal-like (SH-SY5Y-derived) and microglial cell lines, reporting effects on mitochondrial and glycolytic bioenergetic parameters.

Mechanism

Overlaps mechanistically with the mitochondrial-function finding above; see the overlap map. No separate ATP-flux mechanism beyond general bioenergetic modulation was identified.

Counter-evidence held on record

Single in vitro study, no human data, no dosing or supplement implication of any kind.